At first pass looks as though there is not much in the way of...

At first pass looks as though there is not much in the way of new patient data, although specifics on patient outcomes are good to see - based on previous data cut response rates though. Was hoping for more but expected the same.

Curious as to why they’ve left out the fact they have just achieved FDA Fast Track designation for CF33s expansion trial. Surely that’s a compelling bit of information. Given FDA approval is the ultimate goal and timelines are on everyone’s mind, I would’ve thought that would be a no brainer bit of content to a fresh audience?!